Inclusion Criteria:

- Histologically confirmed diagnosis of non-squamous NSCLC; Stage ⅢA-ⅢB(not suitable
for surgery) or stage Ⅳ(only single-site single transfer );

- Untreated patients, or who completed ≤ 2 cycles of first-line chemotherapy
(chemotherapy regimen: paclitaxel, docetaxel + cisplatin) within the previous month;

- Patients with tumor EGFR mutation positive (exon 19 deletion mutation or exon 21
L858R substitution mutation);

- Patients must be informed of the investigational nature of the study and must sign an
informed consent form;

- Presence of at least one measurable/evaluable according to RECIST criteria.

- ECOG performance Status 0-2 ;

- Patients must have a life expectancy > 12 weeks;

- Patients with laboratory values as follows:WBC＞4.0 x 109/L; ANC≥1.5 x 109/L; PLT≥100
x 109/L; HGB≥10 g/dL; CR≤1.5 x ULN; TBIL＜1.5 x ULN; AST and ALT≤1.5 x ULN; LDH≤1.5 x
ULN; AKP≤5 x ULN;

- FEV 1≥1.0L and ＞50% Corresponding normal values;

- Patient candidate to standard platinum-based chemotherapy;

- Patients must be nonpregnant and non-lactating.Patients of childbearing potential
must implement an effective method of contraception during the study. All female
Patients, except those who are postmenopausal or surgically sterilized, must have a
negative pre-study serum or urine pregnancy test.

Exclusion Criteria:

- Any evidence of clinically active interstitial lung disease;

- Diagnosis of any other malignancy during the last 5 years, except for in situ
carcinoma of cervix uterine and squamous cell carcinoma of the skin；

- Pregnancy or lactating；

- Serious concomitant infection;

- MI within preceding 6 months or symptomatic heart disease, including unstable angina,
congestive heart failure or uncontrolled arrhythmia;

- As judged by the investigator, any evidence of severe or uncontrolled systemic
disease (eg, unstable or uncompensated respiratory, cardiac, hepatic, or renal
disease);

- Patients who are not suitable to participate in the trial according to researchers.